petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI.
Authors
Affiliations (7)
Affiliations (7)
- CNRS, Univ. Bordeaux, Bordeaux INP, LABRI, UMR5800, Talence, F-33400, France. [email protected].
- CNRS, Univ. Bordeaux, Bordeaux INP, LABRI, UMR5800, Talence, F-33400, France.
- ITACA, Universitat Politècnica de València, Valencia, 46022, Spain.
- Department of Neurology, Institute of Memory and Alzheimer's Disease, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, 75013, France.
- Institut du Cerveau - ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, 75591, France.
- Service de Neurologie des Maladies Neurodégénératives, Centre Mémoire Ressources Recherche, CHU Bordeaux, Bordeaux, F-33000, France.
- Institut des Maladies Neurodégénératives, Univ. de Bordeaux, CNRS, UMR 5293, Bordeaux, F-33000, France.
Abstract
Quantification of amyloid plaques (A), neurofibrillary tangles (T<sub>2</sub>), and neurodegeneration (N) using PET and MRI is critical for Alzheimer's disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration. We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T<sub>2</sub>, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge. petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T<sub>2</sub>, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T<sub>2</sub>/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance. petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.